P2X7 is reported to be present on some primary human AML cells [46,47], but it remains unknown if the use of P2X7 antagonism in patients with blood cancers to prevent GVHD would increase cancer relapse. Here, P2RX7 is linked to hematopoietic and lymphoid system neoplasm.